To date, these signatures have not replaced the currently used prognostic and predictive factors in the management of BC, but provide useful complementary information to traditional clinicopathological parameters in the clinically intermediate risk group of patients, in particular those with ER‐positive, HER2‐negative early‐stage BC. The gene discussed is ERBB2; the disease is breast cancer.